west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "耐药机制" 5 results
  • 深部真菌感染的耐药机制研究进展

    【摘要】随着深部真菌感染日益增加及抗真菌药物的广泛应用,深部真菌耐药现象也日益突出。近十年以来,虽有较多新型抗真菌感染药物相继研发并应用于临床,但国内外已有较多对其耐药的病案报道。真菌面对唑类等强大的抗真菌药物也不断产生着严重的耐药性,并迅速使一些院内真菌感染陷入了无药可选的境地。因此,研究真菌的耐药机制并寻找新的抗真菌药物已成当务之急。现就按照抗真菌药物分类,对近年来国内外深部真菌感染的耐药机制的研究进展进行综述,以明确深部真菌耐药发生的诱因、机制,为指导临床合理使用抗真菌药物;尽可能减少深部真菌耐药的发生及研究新一代抗真菌药物提供参考。

    Release date: Export PDF Favorites Scan
  • 抗菌药物耐药机制和抗感染治疗研究进展

    目前临床应用的抗菌药物大部分是在1936~1968年间发现的,过去的40余年仅发现了3种具有新型抗菌作用机制的药物,即利奈唑胺、达托霉素和Mutilins。有限的抗菌药物资源和抗菌药物滥用使得细菌迅速获得耐药性,细菌对抗菌药物的耐药性已成为全球性问题,给抗感染治疗带来了严峻挑战,NDM-1耐药基因的出现更是雪上加霜。今年世界卫生日的主题为“抵御耐药性:今天不采取行动,明天就无药可用”,世界卫生组织号召所有主要利益相关方,包括决策者和计划者、公众和患者、行医者和处方者、药剂师和药物供应商以及制药业,采取行动并负起责任,抵御抗菌药物耐药性。近年来,抗菌药物耐药机制的研究揭示了新型耐药机制,同时,新药物、新的致病机制和治疗手段的发现为抵御耐药菌感染打下了坚实的理论基础。本文拟就这两方面内容做一综述。

    Release date:2016-08-30 11:58 Export PDF Favorites Scan
  • Study of OprD2 gene polymorphism in imipenem-resistant Pseucionionas aeruginosa

    ObjectiveTo explore the relationship between imipenem-resistant Pseudomonas aeruginosa (IRPA) and outer membrane porin protein OprD2 gene mutation.MethodsIRPA strains (n=30) and imipenem-sensitive Pseudomonas aeruginosa strains (n=30) isolated from the clinical specimens in the First Affiliated Hospital of Chengdu Medical College from December 2018 to December 2019 were collected. Bacteria identification and drug sensitivity experiments were performed by VITEK-2 Compact combined with Kirby-Bauer method. Quantitative real-time polymerase chain reaction was used to detect the expression levels of OprD2 gene in the imipenem-resistant group and the imipenem-sensitive group, and then the strains with decreased expression were sequenced.ResultsThe expression level of OprD2 gene in the imipenem-resistant group was significantly lower than that in the imipenem-sensitive group (P=0.048). Compared with the X63152 sequence, all the 11 Pseudomonas aeruginosa strains with significantly decreased OprD2 expression carried genetic variation, which occurred in coding regions. The variation sites presented diversity. The missense mutation of c.308C→G, c.344A→C, c.379G→C, c.471G→C, c.508T→C, c.553G→C, c.556-558CCG→GGC and c.565-566TG→AC caused amino acid change in the loop L2 and L3 of OprD2 porin, which affected the binding to imipenem. In addition, the mutations at 127, 169-171, 175, 177, 604, 628-630, 688, 719, 785, 826, 828, 842-843, 886, 901, 928-930, 934, 936, 944-945, 1039, 1041 and 1274 all resulted in the changes of amino acid. We also detected a deletion (c.1114-1115delAT) and other nonsense mutations. Large fragment deletion of OprD2 gene occurred in Strain 12. ConclusionsThe mutation and deletion of OprD2 gene can reduce the expression lever of OprD2 gene, leading to the resistance to imipenem of Pseudomonas aeruginosa. The variation of OprD2 gene of IRPA from clinical strains is diverse.

    Release date:2020-08-25 10:08 Export PDF Favorites Scan
  • Research status and prospects of ferroptosis in hepatocellular carcinoma and its drug resistance

    Objective To summarize the papers about the research status and prospects of ferroptosis in hepatocellular carcinoma (HCC) and its drug resistance in recent years in order to provide directions and ideas for the treatment of HCC. Method The relevant literatures at home and abroad in recent years about ferroptosis in HCC and its drug resistance were reviewed. Results The mechanism of ferroptosis in the development and drug resistance of HCC was complicated, involving multiple protein and molecular pathways. Ferroptosis played an important role in improving chemotherapy and sorafenib resistance, and it had a broad application prospect in HCC. Conclusions The molecular mechanism of ferroptosis in HCC and its drug resistance has not been fully elucidated. Further research on the mechanism of ferroptosis in HCC may provide new molecular therapeutic targets for HCC. Ferroptosis has a broad application prospect in the treatment of HCC.

    Release date: Export PDF Favorites Scan
  • Research progress on influencing factors of drug resistance of carbapenem-resistant Klebsiella pneumoniae

    In recent years, with the wide application of carbapenems, the resistance of Enterobacterium to carbapenems has become increasingly high, leading to a large number of carbapenem-resistant Klebsiella pneumoniae (CRKP). These bacteria are often resistant to many different types of antibacterial drugs, including carbapenems, which leads to clinical treatment failure and seriously threatens the life safety of patients. Currently, these bacteria have become an independent risk factor for patients’ death. This article reviews the drug resistance, infection status and influencing factors, and medication therapy of CRKP, in order to facilitate the clinical diagnosis, treatment, and disease process control of CRKP infection, and provide reference for curbing bacterial drug resistance.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content